SG Americas Securities
AVBP icon

SG Americas Securities’s ArriVent BioPharma AVBP Stock Holding History

SG Americas Securities’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$862K Sell
24,805
-23,911
-49% -$706K ﹤0.01% 1980
2026
Q1 		$1.12M Sell
48,716
-2,721
-5% -$61.5K ﹤0.01% 1691
2025
Q4 		$1.03M Buy
51,437
+14,495
+39% +$302K ﹤0.01% 1983
2025
Q3 		$682K Buy
36,942
+9,469
+34% +$186K ﹤0.01% 1835
2025
Q2 		$598K Buy
27,473
+4,793
+21% +$99.5K ﹤0.01% 1541
2025
Q1 		$419K Buy
22,680
+10,873
+92% +$266K ﹤0.01% 1924
2024
Q4 		$315K Sell
11,807
-120
-1% -$3.44K ﹤0.01% 1750
2024
Q3 		$280K Buy
+11,927
New +$271K ﹤0.01% 2217

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SG Americas Securities's AVBP Position: Q2 2026 in Review

SG Americas Securities reduced its ArriVent BioPharma (AVBP) stake by 49% in Q2 2026, selling an estimated $706K and leaving 24,805 shares worth $862K. The position accounts for ﹤0.01% of the portfolio, ranked #1980.

SG Americas Securities first reported a position in AVBP in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.12M in Q1 2026. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • SG Americas Securities held 24,805 shares of ArriVent BioPharma worth $862K as of Q2 2026.
  • SG Americas Securities sold 23,911 ArriVent BioPharma shares in Q2 2026, an estimated $706K.
  • ArriVent BioPharma made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1980 holding.
  • SG Americas Securities first reported a position in ArriVent BioPharma in Q3 2024 and has held it in 8 quarters since.
  • SG Americas Securities's ArriVent BioPharma position peaked at $1.12M in Q1 2026.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.